Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia

25 Jan 2017

Abstract excerpt

ALL, and in some T-cell ALLs (T-ALLs), predicting in vivo activity as a single agent and in combination with dexamethasone and vincristine. Unexpected sensitivity to dasatinib with half maximal inhibitory concentration values below 20 nM was detected in 2 independent T-ALL cohorts, which correlated with similar cytotoxic activity of the SRC inhibitor KX2-391 and inhibition of SRC phosphorylation. A patient with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to Acute Myeloid Leukemia Research
Share to Chronic Myeloid Leukemia Treatments

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28122742
DOI: 10.1182/blood-2016-09-738070

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemiaPMID 28122742Read ↗

Drug response profiling guides precision therapy in relapsed and refractory childhood acute lymphoblastic leukemiaSemantic proximity Read ↗

In silico and preclinical drug screening identifies dasatinib as a targeted therapy for T-ALLSemantic proximity Read ↗

Multi-omics molecular phenotyping of childhood acute lymphoblastic leukemia cell lines reveals novel drug vulnerabilitiesSemantic proximity Read ↗

Advancing Chemogenomic Strategies for Functional Precision Medicine in Relapsed/Refractory T-ALL and ETP-ALL: TheGimema ALL2720 TrialSemantic proximity Read ↗

Ex Vivo Drug Responses and Molecular Profiles of 597 Pediatric Acute Lymphoblastic Leukemia PatientsSemantic proximity Read ↗

Mutational and functional genetics mapping of chemotherapy resistance mechanisms in relapsed acute lymphoblastic leukemia.Semantic proximity Read ↗

Dasatinib response in acute myeloid leukemia is correlated with FLT3/ITD, PTPN11 mutations and a unique gene expression signature.Semantic proximity Read ↗

A chemogenomic approach to identify personalized therapy for patients with relapse or refractory acute myeloid leukemia: results of a prospective feasibility study.Semantic proximity Read ↗

Ex vivo drug responses and molecular profiles of 597 pediatric acute lymphoblastic leukemia patientsSemantic proximity Read ↗

Ex vivo venetoclax sensitivity predicts clinical response in acute myeloid leukemia in the prospective VenEx trialSemantic proximity Read ↗

Positive impact of high-throughput drug sensitivity assay and salvage autologous CD19 CAR-T therapy on second marrow relapse of acute lymphoblastic leukemia with NT5C2 mutationSemantic proximity Read ↗

Repositioning of FDA-approved anti-cancer drugs for fatal blast crisis CML by integrated high-throughput genomic and artificial intelligence-based drug discovery analyses of pan-leukemic genetic abnormalities: Implications in post-COVID-19 eraSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.